Fig. 3
From: Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial
Secondary outcome measures. Estimated mean group changes for clinical scores. Estimated mean group changes from baseline (W0) in the ADCS-ADL, ADAS-Cog11, MMSE and NPI scores following 12 weeks (W12), 24 weeks (W24) 36 weeks (W36) and 52 weeks (W52) of PC-rTMS and sham-rTMS. Y-axis of each outcome was adapted in order to considering all depicted descending trend as a worsening. A GLMM estimated mean score change from baseline for the ADCS-ADL; scores range from 0 to 78, with lower scores indicating worse function. B GLMM estimated mean score change from baseline for the ADAS-Cog11; scores range from 0 to 70, with higher scores indicating worse cognition. C GLMM estimated mean score change from baseline on the MMSE; scores range from 0 to 30, with lower scores indicating worse cognition. D. GLMM mean score change from baseline on the NPI; scores range from 0 to 144, with higher scores indicating worse behavioural symptoms. E. GLMM mean score change from baseline on the FBI; scores range from 0 to 18, with higher scores indicating better cognitive performance. Baseline is plotted at Week 0, which is the baseline measurement before the first rTMS session. Error bars indicate standard errors